Welcome to our dedicated page for Covalon Technologies news (Ticker: CVALF), a resource for investors and traders seeking the latest updates and insights on Covalon Technologies stock.
Covalon Technologies Ltd. reports company developments across advanced medical technologies for vascular access, infection prevention, wound care, and surgical consumables. Recurring updates describe clinical education, healthcare-conference activity, and product use around contamination of intravenous connections, healthcare-associated infection risk, skin integrity, and patient-care workflows.
Covalon news also includes fiscal results, management discussion and analysis availability, shareholder meeting matters, director compensation through deferred share units, and amendments to governance documents and incentive plans. Product-specific coverage includes solutions such as CovaClear IV Cover dressings and VALGuard Vascular Access Line Guard.
Covalon (OTCQX:CVALF) will release its Q2 fiscal 2026 results on Thursday, May 21, 2026, before markets open. Management will host a conference call and live webcast at 8:30 a.m. ET to discuss the results and take investor questions.
Covalon Technologies (OTCQX: CVALF) reported commercial and clinical engagement milestones across vascular access, infection prevention, and wound care on April 15, 2026. The company cited strong clinician interest at the Infusion Nurses Society meeting, inclusion of contamination education at APIC and AVA 2026, and SAWC wound care outreach.
Covalon highlighted its VALGuard Line Guard and CovaClear IV Cover dressings as differentiated solutions gaining exposure through key conferences and KOL presentations.
Covalon (OTCQX: CVALF) will attend the Infusion Nurses Society 2026 Annual Meeting in Louisville, KY, April 11–14, 2026, showcasing vascular access infection‑prevention solutions.
The company will highlight VALGuard and CovaClear, and host a podium presentation by Dr. Nancy Moureau on contamination of IV connections and CABSI risk.
Covalon (OTCQX: CVALF) granted an aggregate of 97,674 Deferred Share Units (DSUs) to four non-employee directors who elected DSU payment for fiscal 2026 fees. The DSUs were issued under the Amended and Restated Omnibus Long-Term Incentive Plan adopted March 25, 2026, and vest 12 months from grant. The deemed value used was the TSX Venture closing price before grant of $1.72 per share.
Covalon (OTCQX: CVALF) reported shareholder approval of all items at its March 25, 2026 Annual General and Special Meeting. 10,157,014 shares (36.777%) were represented. Approved actions include election of directors, PwC appointment, articles amendment to allow preferred shares, amended by-law no.1, advance notice by-law, amended omnibus LTIP, and 150,000 options granted to COO Kim Crooks.
Detailed vote tallies showed strong support for directors and auditors, 89.133% approval for preferred-share authorization, and 96.045% approval for the COO option grant.
Covalon (OTCQX: CVALF, TSXV: COV) will hold its annual meeting of shareholders on Wednesday, March 25, 2026 at 2:00pm ET in a virtual-only format via live webcast.
The meeting will feature a presentation by CEO Brent Ashton and a Q&A session. Registered shareholders and duly appointed proxyholders can attend, participate, and vote online; guests may attend in view-only mode. Meeting access: https://virtual-meetings.tsxtrust.com/en/1871, Meeting ID 1871, Password covalon2026.
Covalon (OTCQX:CVALF) reported fiscal Q1 2026 results for the quarter ended December 31, 2025, with revenue $6.89M, gross margin 58.2%, adjusted EBITDA $426,829, and net income $125,377. Cash was approximately $17.9M after a $4.1M special dividend.
The company highlighted new customer additions, system-wide approval of VALGuard at a 300+ site IDN, a Vizient contract via HARTMANN USA, positive clinical validation reducing CLABSIs, and upcoming industry presentations and a Feb 25, 2026 webcast.
Covalon (OTCQX:CVALF) is sponsoring a continuing-education webinar on IV line contamination and CABSI prevention, presented by vascular access expert Dr. Nancy Moureau and hosted by the Association for Vascular Access (AVA).
The live session is scheduled for Tuesday, February 24, 2026 at 2:00 PM EST with a rebroadcast at 7:00 PM EST, and offers accredited continuing-education credit through AVA.
Covalon (OTCQX: CVALF) will release its Q1 Fiscal 2026 results on Wednesday, February 25, 2026, before markets open. A live conference call and webcast to discuss the results is scheduled for February 25, 2026 at 8:30am ET.
Investors can join via webcast or dial the North American toll-free number; a recording and filings will be available on the company website and SEDAR PLUS.
Covalon Technologies (OTCQX: CVALF) reported fiscal 2025 results for the year ended Sept 30, 2025, with FY revenue of $32.82M, up 5% year-over-year, and Q4 revenue of $8.69M, the company’s highest quarter of FY25.
The company reported FY net income of $2.06M, adjusted EBITDA of $3.71M, gross margin of 53% (56% excluding inventory write-offs), and recorded $715,983 in inventory provisions. Covalon paid its first-ever special dividend of $0.15 CAD per share, leaving cash of $17.0M and no debt as of Dec 5, 2025. Management named Katie Martinovich as CFO. Key commercial wins included a >50% Q4 increase in U.S. vascular access sales and a >$1M initial purchase order from a new U.S. partner for FY26 Q2 delivery.